Literature DB >> 7339345

[Chemotherapy of soft tissue sarcomas].

D K Hossfeld, S Seeber, E Siemers, C G Schmidt.   

Abstract

Sixty-two patients with metastatic soft tissue sarcomas of various histological types were treated with Cyvadic. No chemotherapy had been given previously. Complete remission (CR) was obtained in 10% and complete plus partial remission (PR) in 20% of the patients. Mean duration of CR was 25 months, that of PR 2.5 months. Median survival time of responders was 28 months, that of nonresponders 14 months. Chemotherapy with a combination of ifosfamide plus cisplatin given to patients with primary or secondary resistance to Cyvadic led to CR + PR in 50% of the patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7339345     DOI: 10.1007/bf01286830

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  8 in total

1.  E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma.

Authors:  V H Bramwell; A Brugarolas; H T Mouridsen; F Cheix; F De Jager; A T van Oosterom; C P Vendrik; H M Pinedo; R Sylvester; M De Pauw
Journal:  Eur J Cancer       Date:  1979-12       Impact factor: 9.162

2.  [Chemotherapy in advanced sarcomas (author's transl)].

Authors:  W Bierbaum; K Bremer; N Firusian; M Higi; N Niederle; M E Scheulen; C G Schmidt; S Seeber
Journal:  Dtsch Med Wochenschr       Date:  1981-09-11       Impact factor: 0.628

3.  Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma.

Authors:  R Becher; S Seeber; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

4.  Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas.

Authors:  B S Yap; L H Baker; J G Sinkovics; S E Rivkin; R Bottomley; T Thigpen; M A Burgess; R S Benjamin; G P Bodey
Journal:  Cancer Treat Rep       Date:  1980-01

5.  Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD).

Authors:  R H Blum; J M Corson; R E Wilson; J S Greenberger; G P Canellos; E Frei
Journal:  Cancer       Date:  1980-10-15       Impact factor: 6.860

6.  Cis-dichlorodiammineplatinum(II) in metastatic soft tissue sarcomas.

Authors:  C P Karakousis; O A Holtermann; E D Holyoke
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

7.  Chemotherapy of sarcoma. A comparison of three regimens.

Authors:  S Subramanian; E Wiltshaw
Journal:  Lancet       Date:  1978-04-01       Impact factor: 79.321

8.  High-dose methotrexate as secondary chemotherapy in metastatic soft-tissue sarcomas.

Authors:  C P Karakousis; U Rao; M Carlson
Journal:  Cancer       Date:  1980-09-15       Impact factor: 6.860

  8 in total
  1 in total

1.  Treatment, outcomes, and demographics in sinonasal sarcoma: a systematic review of the literature.

Authors:  Mitchell R Gore
Journal:  BMC Ear Nose Throat Disord       Date:  2018-03-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.